 Multiple Sclerosis
"Multiple Sclerosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Descriptor ID |
D009103
|
| MeSH Number(s) |
C10.114.375.500 C10.314.350.500 C20.111.258.250.500
|
| Concept/Terms |
Multiple Sclerosis- Multiple Sclerosis
- Sclerosis, Multiple
- Sclerosis, Disseminated
- Disseminated Sclerosis
- MS (Multiple Sclerosis)
|
Below are MeSH descriptors whose meaning is more general than "Multiple Sclerosis".
Below are MeSH descriptors whose meaning is more specific than "Multiple Sclerosis".
This graph shows the total number of publications written about "Multiple Sclerosis" by people in this website by year, and whether "Multiple Sclerosis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 | | 1996 | 1 | 0 | 1 | | 1997 | 6 | 0 | 6 | | 1998 | 2 | 0 | 2 | | 1999 | 2 | 0 | 2 | | 2000 | 1 | 0 | 1 | | 2001 | 4 | 0 | 4 | | 2002 | 2 | 1 | 3 | | 2003 | 9 | 0 | 9 | | 2004 | 3 | 1 | 4 | | 2005 | 15 | 0 | 15 | | 2006 | 11 | 2 | 13 | | 2007 | 14 | 1 | 15 | | 2008 | 13 | 1 | 14 | | 2009 | 15 | 0 | 15 | | 2010 | 14 | 0 | 14 | | 2011 | 15 | 2 | 17 | | 2012 | 14 | 2 | 16 | | 2013 | 8 | 3 | 11 | | 2014 | 12 | 0 | 12 | | 2015 | 9 | 0 | 9 | | 2016 | 13 | 5 | 18 | | 2017 | 21 | 2 | 23 | | 2018 | 21 | 1 | 22 | | 2019 | 15 | 1 | 16 | | 2020 | 16 | 1 | 17 | | 2021 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Multiple Sclerosis" by people in Profiles.
-
Kapitza C, Chunder R, Scheller A, Given KS, Macklin WB, Enders M, Kuerten S, Neuhuber WL, Wörl J. Murine Esophagus Expresses Glial-Derived Central Nervous System Antigens. Int J Mol Sci. 2021 Mar 22; 22(6).
-
Swanson CW, Proessl F, Stephens JA, Miravalle AA, Fling BW. Non-invasive brain stimulation to assess neurophysiologic underpinnings of lower limb motor impairment in multiple sclerosis. J Neurosci Methods. 2021 05 15; 356:109143.
-
Kwilasz AJ, Green Fulgham SM, Duran-Malle JC, Schrama AEW, Mitten EH, Todd LS, Patel HP, Larson TA, Clements MA, Harris KM, Litwiler ST, Harvey LO, Maier SF, Chavez RA, Rice KC, Van Dam AM, Watkins LR. Toll-like receptor 2 and 4 antagonism for the treatment of experimental autoimmune encephalomyelitis (EAE)-related pain. Brain Behav Immun. 2021 03; 93:80-95.
-
Toliver JC, Barner JC, Lawson KA, Rascati KL. Use of a claims-based algorithm to estimate disease severity in the multiple sclerosis Medicare population. Mult Scler Relat Disord. 2021 Apr; 49:102741.
-
Nicholas JA, Shin RK, Alvarez E, Hendin B, Nair KV, Lublin FD. Pandemic forward: Lessons learned and expert perspectives on multiple sclerosis care in the COVID-19 era. Mult Scler Relat Disord. 2021 04; 49:102715.
-
Montgomery TL, Künstner A, Kennedy JJ, Fang Q, Asarian L, Culp-Hill R, D'Alessandro A, Teuscher C, Busch H, Krementsov DN. Interactions between host genetics and gut microbiota determine susceptibility to CNS autoimmunity. Proc Natl Acad Sci U S A. 2020 11 03; 117(44):27516-27527.
-
Toliver J, Barner JC, Lawson K, Sonawane K, Rascati K. Replication of a Claims-based Algorithm to Estimate Multiple Sclerosis Disease Severity in a Commercially Insured Population. Mult Scler Relat Disord. 2020 Nov; 46:102539.
-
Hartung HP, Berger T, Bermel RA, Brochet B, Carroll WM, Holmøy T, Karabudak R, Killestein J, Nos C, Patti F, Ross AP, Vanopdenbosch L, Vollmer T, Buffels R, Garas M, Kadner K, Manfrini M, Wang Q, Freedman MS. Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2020 Nov; 46:102492.
-
Kalron A, Ehling R, Baert I, Smedal T, Rasova K, Heric-Mansrud A, Elorriage I, Nedeljkovic U, Tachino A, Gargul L, Gusowski K, Cattaneo D, Borgers S, Hebert J, Dalgas U, Feys P. Improving our understanding of the most important items of the Multiple Sclerosis Walking Scale-12 indicating mobility dysfunction: Secondary results from a RIMS multicenter study. Mult Scler Relat Disord. 2020 Nov; 46:102511.
-
Hidde MC, Howell M, DeBord A, Leach HJ. Acute High-Intensity Interval Exercise in Multiple Sclerosis with Mobility Disability. Med Sci Sports Exerc. 2020 09; 52(9):2055.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|